Anzeige
Mehr »
Donnerstag, 24.07.2025 - Börsentäglich über 12.000 News
Neubewertung voraus? Wird die Aktivierung der EU-Lizenz zum Kurs-Katalysator für die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EGRS | ISIN: CA29842P1053 | Ticker-Symbol: X43
Frankfurt
23.07.25 | 08:31
4,100 Euro
-1,91 % -0,080
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
EUPRAXIA PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
EUPRAXIA PHARMACEUTICALS INC 5-Tage-Chart

Aktuelle News zur EUPRAXIA PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiEUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer1
08.07.Eupraxia Pharmaceuticals Inc: Eupraxia doses first patient in phase 2b Resolve trial1
08.07.Stocks in Play: Eupraxia Pharmaceuticals Inc.-
08.07.Eupraxia Pharmaceuticals Inc.: Eupraxia Doses First Patient in Phase 2b Placebo-Controlled Portion of EP-104GI RESOLVE Trial in Eosinophilic Esophagitis48Dosing of the first patient in Phase 2b marks an important transition of the RESOLVE trial from a Phase 2a open-label study to a Phase 2b placebo-controlled study. This is a critical step required...
► Artikel lesen
EUPRAXIA PHARMACEUTICALS Aktie jetzt für 0€ handeln
08.07.EUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer1
16.06.Canaccord Genuity initiates Eupraxia stock with spec. buy on EoE treatment2
03.06.Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders82VICTORIA, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging...
► Artikel lesen
07.05.Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 20251
07.05.Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results132Data from Phase 1b/2a RESOLVE suggests EP-104GI has significant potential to improve the standard of care for patients with Eosinophilic Esophagitis (EoE) Cash runway to fund operations out to...
► Artikel lesen
05.05.Eupraxia Pharmaceuticals Inc: Eupraxia talks treatment outcomes in phase 1b/2a trial2
05.05.Stocks in Play: Eupraxia Pharmaceuticals Inc.-
05.05.EUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer2
24.04.EUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer1
21.03.Eupraxia Pharmaceuticals reports Q4 results3
20.03.Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results157VICTORIA, BC, March 20, 2025 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology...
► Artikel lesen
26.02.Eupraxia Pharmaceuticals is undervalued, Research Capital says2
25.02.Eupraxia Pharmaceuticals Inc: Eupraxia talks EP-104GI Resolve study clinical data2
25.02.Eupraxia reports progress in EoE drug trial with promising results1
25.02.Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis134Histological scores and symptom scores continue to improve as EP-104GI dose, and area of esophageal coverage, increase Cohort 6 showed the greatest symptom relief...
► Artikel lesen
25.02.EUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer-
Weiter >>
33 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1